New post-hoc analyses from the large-scale GRIPHON trial assessing selexipag in patients with pulmonary arterial hypertension (PAH) demonstrate that early, aggressive treatment after diagnosis is associated with the greatest benefits, irrespective of background therapy .
Around a third of PAH patients currently die within 5 years of diagnosis; early recognition and prompt treatment of the disease are key to achieving sustained long-term benefits . The GRIPHON study evaluated the long-term efficacy and safety of oral selexipag in 1,156 patients with PAH across 181 centres from 39 countries. It is the largest randomised, controlled, outcome trial ever conducted in patients with PAH and generated data that is still being analysed. A 40% reduction in the primary composite endpoint of morbidity/mortality was met (i.e. disease progression, worsening of PAH resulting in hospitalisation, initiatio...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« A Randomised Controlled Trial of a Smoking Cessation Smartphone Application Next Article
Sleep Apnoea Severity Has a Non-linear Relationship with Acute Myocardial Infarction Risk »
Table of Contents: ATS 2019
Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics
Critical Care Medicine
Pulmonary Vascular Disease and Interstitial Lung Disease
Paediatric Pulmonary Medicine
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.